沙库巴曲缬沙坦改善癌症治疗所致心肌病的心肌功能和结构 - Suppr

Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy.

作者信息

Martín-García Ana, Díaz-Peláez Elena, Martín-García Agustín C, Sánchez-González Javier, Ibáñez Borja, Sánchez Pedro L

机构信息

Servicio de Cardiología, Hospital Universitario de Salamanca-IBSAL, Universidad de Salamanca, Salamanca, Spain; CIBERCV, Instituto de Salud Carlos III, Madrid, Spain.

Servicio de Cardiología, Hospital Universitario de Salamanca-IBSAL, Universidad de Salamanca, Salamanca, Spain.

出版信息

Rev Esp Cardiol (Engl Ed). 2020 Mar;73(3):268-269. doi: 10.1016/j.rec.2019.07.006. Epub 2019 Aug 12.

DOI:10.1016/j.rec.2019.07.006

PMID:31416729

Abstract

摘要

相似文献

Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy.沙库巴曲缬沙坦改善癌症治疗所致心肌病的心肌功能和结构

Rev Esp Cardiol (Engl Ed). 2020 Mar;73(3):268-269. doi: 10.1016/j.rec.2019.07.006. Epub 2019 Aug 12.

Myocardial work improvement after sacubitril-valsartan therapy: a new echocardiographic parameter for a new treatment.沙库巴曲缬沙坦治疗后的心肌做功改善：新治疗的新超声心动图参数。

J Cardiovasc Med (Hagerstown). 2020 Mar;21(3):223-230. doi: 10.2459/JCM.0000000000000932.

Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.沙库巴曲缬沙坦在真实世界实践中的应用：晚期心力衰竭患者的经验和系统评价。

Cardiovasc Drugs Ther. 2019 Jun;33(3):307-314. doi: 10.1007/s10557-019-06858-0.

The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.沙库巴曲缬沙坦治疗射血分数降低的心力衰竭的逆重构反应。

Cardiovasc Ther. 2018 Aug;36(4):e12435. doi: 10.1111/1755-5922.12435. Epub 2018 Jun 7.

Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.血管紧张素受体脑啡肽酶抑制剂对射血分数降低的心力衰竭患者肺动脉僵硬度的影响。

Int J Cardiovasc Imaging. 2021 Jan;37(1):165-173. doi: 10.1007/s10554-020-01973-8. Epub 2020 Aug 19.

Profound Vasoplegia During Sacubitril/Valsartan Treatment After Heart Transplantation.心脏移植后沙库巴曲缬沙坦治疗期间出现严重的血管麻痹。

Can J Cardiol. 2018 Mar;34(3):343.e5-343.e7. doi: 10.1016/j.cjca.2017.12.004. Epub 2017 Dec 11.

"Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.“真实世界”中沙库巴曲缬沙坦在未经选择的心衰患者中的使用情况：来自瑞典心衰注册登记研究的数据。

Cardiovasc Drugs Ther. 2019 Jun;33(3):315-322. doi: 10.1007/s10557-019-06873-1.

Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.评估在药师诊所管理下用于射血分数降低心衰（HFrEF）的沙库巴曲缬沙坦的安全性和耐受性。

Am J Cardiovasc Drugs. 2018 Apr;18(2):143-151. doi: 10.1007/s40256-018-0264-5.

Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.射血分数降低的心力衰竭患者实际应用中转换为沙库巴曲缬沙坦治疗：一项队列研究。

Open Heart. 2020 Oct;7(2). doi: 10.1136/openhrt-2020-001305.

Sacubitril/valsartan in the treatment of cancer therapy-related cardiac dysfunction.沙库巴曲缬沙坦治疗癌症治疗相关的心功能不全

Int J Cardiol. 2020 Nov 1;318:130. doi: 10.1016/j.ijcard.2020.06.041. Epub 2020 Jun 28.

引用本文的文献

Sacubitril/valsartan attenuated myocardial inflammation, fibrosis, apoptosis and promoted autophagy in doxorubicin-induced cardiotoxicity mice via regulating the AMPKα-mTORC1 signaling pathway.沙库巴曲缬沙坦通过调节AMPKα-mTORC1信号通路减轻阿霉素诱导的心脏毒性小鼠的心肌炎症、纤维化、细胞凋亡并促进自噬。

Mol Cell Biochem. 2025 Mar;480(3):1891-1908. doi: 10.1007/s11010-024-05117-7. Epub 2024 Sep 20.

Sacubitril/valsartan in Heart Failure and Beyond-From Molecular Mechanisms to Clinical Relevance.沙库巴曲缬沙坦在心力衰竭及其他方面——从分子机制到临床意义

Rev Cardiovasc Med. 2022 Jun 24;23(7):238. doi: 10.31083/j.rcm2307238. eCollection 2022 Jul.

Pharmacotherapy for Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Childhood Cancer Survivors.癌症治疗相关心脏功能障碍和心力衰竭患儿的药物治疗。

Paediatr Drugs. 2023 Nov;25(6):695-707. doi: 10.1007/s40272-023-00585-8. Epub 2023 Aug 28.

Effectiveness of sacubitril/valsartan for patients with cancer therapy‑related cardiac dysfunction: A systematic review of descriptive studies.沙库巴曲缬沙坦对癌症治疗相关心脏功能障碍患者的有效性：描述性研究的系统评价

Oncol Lett. 2023 Feb 2;25(3):108. doi: 10.3892/ol.2023.13694. eCollection 2023 Mar.

Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity.中性肽链内切酶抑制在预防蒽环类药物所致心脏毒性中的作用

Cancers (Basel). 2023 Jan 3;15(1):312. doi: 10.3390/cancers15010312.

Successful treatment of doxorubicin-induced cardiomyopathy with low-dose sacubitril/valsartan: a case report.低剂量沙库巴曲缬沙坦成功治疗阿霉素诱导的心肌病：一例报告

Eur Heart J Case Rep. 2022 Sep 23;6(10):ytac396. doi: 10.1093/ehjcr/ytac396. eCollection 2022 Oct.

Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology.病例系列：沙库巴曲缬沙坦与可穿戴式心脏复律除颤器联合使用治疗化疗相关急性心力衰竭：心脏肿瘤学中的一种新型成功组合

Front Cardiovasc Med. 2022 Mar 1;9:801143. doi: 10.3389/fcvm.2022.801143. eCollection 2022.

Clinical Profile and Prognosis of a Real-World Cohort of Patients With Moderate or Severe Cancer Therapy-Induced Cardiac Dysfunction.中度或重度癌症治疗引起的心脏功能障碍患者真实世界队列的临床特征与预后

Front Cardiovasc Med. 2021 Oct 29;8:721080. doi: 10.3389/fcvm.2021.721080. eCollection 2021.

Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case Report.沙库巴曲缬沙坦治疗复发性毛细胞白血病患者的心力衰竭：病例报告

Clin Med Insights Cardiol. 2021 Apr 13;15:11795468211010706. doi: 10.1177/11795468211010706. eCollection 2021.

In ®Entresto we trust.我们信赖Entresto（商标名，此处保留英文不翻译）。

Cardiooncology. 2020 Nov 5;6(1):25. doi: 10.1186/s40959-020-00083-7.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献